Ecosystem Focused Therapy for Treating Older Depressed Stroke Survivors
NCT ID: NCT00944762
Last Updated: 2017-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2009-05-01
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ecosystem Focused Therapy in Post Stroke Depression
NCT01624402
Treatment for Post-Stroke Depression
NCT00029172
Social Reward and Its Effect on Brain Functions in Psychotherapies for Mid- and Late-Life Depression
NCT04487730
Mobile Technologies and Post-stroke Depression
NCT04043052
Depression Prevention in Older Spousally-bereaved Adults
NCT04016896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participation in this study will last 1 year. Participants will be randomly assigned to receive one of two treatments: EFT or education in stroke and depression (ESD). Both treatments will be led by therapists and will involve 12 sessions over 25 weeks, with sessions occurring weekly for the first month, every other week for the second 2 months, and monthly for the last 3 months. EFT will involve the following: teaching the participant skills for solving problems related to adjusting to a stroke, altering the participant's physical environment to accommodate new needs, and helping the family or caregiver to assist in the participant's adaptation. ESD will involve providing the participant with education on living with a stroke and depression. Study assessments will include interviews and will occur at nine time points: at baseline and after 2, 3, 6, 10, 14, 20, 26, and 52 weeks. These assessments will measure participants' mood, thinking, and functioning. A family member or caregiver of the older adult participant must also be able to participate in the study, in order both to complete assessments and effectively implement EFT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ecosystem Focused Therapy (EFT)
Participants will receive EFT.
Ecosystem Focused Therapy (EFT)
12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
Education in stroke and depression
Participants will receive education in stroke and depression.
Education in stroke and depression
Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ecosystem Focused Therapy (EFT)
12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
Education in stroke and depression
Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Montgomery-Asberg Depression Rating Scale (MADRS) score greater than or equal to 15
* Admitted to Burke Rehabilitation Hospital soon after ischemic stroke
* Mini Mental State Examination (MMSE) score greater than 17
* Command of English sufficient to comprehend study questionnaires and interventions
* Has family member or professional caregiver willing and able to participate in patient's treatment
Exclusion Criteria
* Moderate to severe aphasia
* Placed in a nursing home after discharge
* Diagnosis of psychotic depression
* High suicide risk (i.e., intent or plan to attempt suicide in near future)
* Presence of illnesses other than stroke (e.g., untreated thyroid or adrenal disease, pancreatic cancer, and lymphoma)
* Taking drugs known to cause depression (e.g., reserpine, alpha-methyl-dopa, steroids)
* Currently being treated for depression with psychotherapy
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Weill Medical College of Cornell University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Victoria Wilkins, PhD
Role: PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University
George S. Alexopoulos, MD
Role: STUDY_DIRECTOR
Weill Medical College of Cornell University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Burke Rehabilitation Hospital
White Plains, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0811010074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.